Biocon Biologics partners to improve global access to cancer treatments and insulin

Home/Pharma News | Posted 05/03/2021 post-comment0 Post your comment

In February 2021, Biocon Biologics joined forces with international organizations to improve access to cancer and diabetes treatments. The India-based biological subsidiary of Biocon, entered into an agreement with the Clinton Health Access Initiative (CHAI) to expand access to cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP) [1]. In addition, they have become the first biosimilar insulin company to partner with the International Diabetes Federation (IDF) to promote and support the latter’s initiatives [2].

Cancer Cell V13I20

Improving access to oncology biosimilars in over 30 countries
Biocon Biologics has strong R & D and manufacturing capabilities through which it can produce lifesaving affordable oncology biosimilars such as trastuzumab and pegfilgrastim. Through its new partnership with CHAI, Biocon Biologics aims to
deliver substantial savings to healthcare systems by enhancing access and availability of these biosimilar cancer therapies in the 25 countries in Africa and 5 countries in Asia, that are currently part of CAP. There will be initial supply of trastuzumab and pegfilgrastim and the arrangement hopes to include more biosimilars in the near future. This is an important step in delivering advanced cancer therapies to patients in low- and middle-income countries (LMICs), whilst ensuring equitable access.

Improving access to insulin globally
Insulin was discovered nearly a century ago, yet millions of diabetes sufferers worldwide do not have affordable access to this life-saving therapy. This is true in both emerging and developed markets, as many in the US struggle to afford insulin therapy. In their recent partnership with IDF, Biocon Biologics hopes to find ways to increase affordable access to insulin and ensure the therapy reaches those who need it most. Having served upwards of two billion doses of insulin to date, the company aims to reach ‘one in five’ insulin-dependent people with diabetes globally. Due to their extensive experience of providing affordable insulins, Biocon Biologics hopes to support IDF to drive policy and action to improve access to the life-saving medication.

This follows Biocon Biologics’ ‘Mission 10 cents’ that it unveiled in 2019, to unlock universal access to high quality human insulin (rh-Insulin), by offering it at less than 10 US cents per day for governments in LMICs.

Related articles
EMA recommends approval of insulin aspart biosimilar Kixelle

Insulin glargine biosimilar Semglee launched in US

US FDA clears Biocon manufacturing sites in Malaysia and India

Biosimilars of insulin glargine

Biosimilars of pegfilgrastim

Biosimilars of trastuzumab

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

References
1. Biocon. Biocon Biologics to offer its oncology biosimilars through cancer access partnership in over 30 countries. 4 February 2021 [homepage on the Internet]. [cited 2021 Mar 5]. Available from: https://www.biocon.com/biocon-biologics-to-offer-its-oncology-biosimilars-through-cancer-access-partnership-in-over-30-countries/
2. Biocon Biologics joins hands with IDF in its mission to promote diabetes care prevention and effective management worldwide. 16 February 2021 [homepage on the Internet]. [cited 2021 Mar 5]. Available from: https://www.biocon.com/biocon-biologics-joins-hands-with-idf-in-its-mission-to-promote-diabetes-care-prevention-and-effective-management-worldwide/

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Licensing agreements signed for ustekinumab biosimilars
IBD 1
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010